Next Phase Newsletter

By Karen Deyo, Director of Product, Israel BD, LSN

Partnering for RESI Boston September, a hybrid event (in-person on September 18, or virtually on September 19-20) launches next Monday, giving registered attendees access to RESI’s unique partnering platform. This platform allows attendees to filter search results with a high degree of precision.

At RESI, unlike other conferences, requesting a meeting with an investor does not require a company to spend most of the initial meeting finding out if they are a fit for the investor or not. Companies can easily determine a list of investors who are interested in their sector, indication, and stage of development before requesting a meeting. Investor profiles are written by Life Science Nation (LSN)’s Investor Research team in a phone interview with each investor, as a requirement before registration.

The RESI Partnering Platform has an integrated video conferencing system, allowing companies to simply log in to the platform and initiate their meetings through their schedule. Make sure to look at the tutorial video below, to see all the features offered by our system!

Premier Platform Sample

Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) is thrilled to be collaborating with the Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at the Redefining Early Stage Investments (RESI) conference, scheduled to take place from September 18-20 at the Boston Park Plaza. The first day will consist of in-person partnering, panels, pitches, and workshops, followed by two virtual partnering days. This collaboration brings together three influential organizations who are tackling the life sciences arena and aims to foster an ecosystem where innovation is nurtured and capital flows seamlessly in Ontario, Canada.

As part of this collaboration, the Government of Ontario and OBIO will be featuring a group of 15 early-stage startups to showcase the latest advancements across:

1. Nutrition
2. Polyphenols to treat chronic diseases
3. Robotic intramuscular injections
4. Wearable artificial kidney for ambulatory dialysis
5. Therapies and solutions in HDAC-driven pathologies, surgical oncology, complex inflammatory skin diseases, and onychomycosis
6. Electronic medical records
7. Non-viral and re-dosable gene therapies

These entrepreneurs will be provided with a unique platform to present their disruptive technologies, engage in one-on-one discussions with potential investors seeking to catalyze growth and expedite the journey toward impactful biotechnological breakthroughs.

With their unique and collaborative innovation ecosystem, Ontario is where companies come to grow and prosper. The same innovative spirit that led to the discovery of insulin in Ontario one hundred years ago has led to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.

Get ready to meet the 15 startups and staff from Government of Ontario and OBIO at RESI Boston in September!

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the ever-evolving finance and investment landscape, family offices have emerged as key players with the potential to drive significant change. These private wealth management firms, entrusted with managing the financial affairs of affluent families, have diversified their portfolios to include investments in a wide array of sectors. One sector that has garnered substantial attention in recent years is healthcare. The intersection of wealth preservation, a family’s medical health profile, and social impact have led many family offices to focus on investing in healthcare, a decision that promises financial returns, improves family legacy, and impacts global well-being.

LSN Collaboration with Stetson Family Office in 2019

LSN launched the Global Family Office BioForum in 2019 in collaboration with the Stetson Family Office to match Family Offices with angel groups, early-stage VCs, and KOLs to help identify and vet early-stage healthcare investment opportunities.  This collaboration was an extension of Chuck Stetson’s visionary initiative on educating family offices to understand how they can impact chronic diseases like Alzheimer’s, Cancer, and Diabetes/Obesity and tackle big global healthcare issues through his Healthcare Impact Foundation. Over the years, the Global Family Office BioForum has witnessed many of these relationships fostered at LSN’s RESI partnering events grow into strategic alliances and investment syndicates that have helped Family Offices move into the early stage healthcare arena.

The Dynamics of Family Offices

Family offices, by their structure, cater to the unique financial needs of high-net-worth families. With a long-term perspective, they prioritize wealth preservation, growth, and the passing down of wealth to future generations. This approach aligns well with the characteristics of the healthcare sector, which, given its essential nature, presents a range of investment opportunities with the potential for both social impact and financial gains. New drug development can take a decade or more and cost hundreds of millions of dollars, while devices, diagnostics, and digital health technology can be developed in three to five years for five to 15 million.  This breadth of choice allows a family office to execute its financial, healthcare, and social impact goals.

Why Healthcare?

As I have stated in the past, planet Earth is in the golden age of life science. Like other investor classes, family offices want a high return rate based on a timeline that matches their money management goals.   The healthcare industry is undergoing rapid transformation, driven by technological advancements, changing demographics, and evolving consumer expectations. These shifts create fertile ground for investment, with opportunities that span pharmaceuticals, biotechnology, medical devices, telemedicine, healthcare IT, and more. The demand for innovative solutions to global health challenges is greater than ever, and family offices are positioning themselves as key contributors to this transformation.

Balancing Profit and Purpose

Family offices are uniquely positioned to balance profit with purpose. Investing in healthcare allows them to pursue financial returns and contribute to improving healthcare access, quality, and affordability. Many family offices see healthcare investments to align their financial goals with their desire to positively enhance their family legacy and society.

Driving Innovation

One of the remarkable aspects of family offices’ involvement in healthcare is their ability to drive innovation. By injecting capital into early-stage startups and research initiatives, family offices provide crucial support to ventures that may otherwise struggle to secure funding. This backing accelerates the development of groundbreaking therapies, technologies, and services, ultimately benefiting patients worldwide.